Treatment of non-small cell lung cancer with brain metastasis

doi:10.3760/cma.j.issn.1673-422X.2015.06.015

Abstract

Abstract: 30%-50% patients with nonsmall cell lung cancer (NSCLC) will occur cerebral metastasis in the course of their illnesses. NSCLC with brain metastases is one of the difficulties in cancer treatment. Treatment measures include surgery, radiotherapy, chemotherapy, biological targeted therapy and so on. The new prognostic scoring system is recommended to predict the prognosis of patients. Individualized treatment methods should be chosen according to prognostic score.

Key words: Carcinoma, non-small cell lung, Neoplasm metastasis, Therapy

Wang Xiaolei, Liu Deze, Liu Weiwei, Jia Lin, Wang Min. Treatment of non-small cell lung cancer with brain metastasis[J]. Journal of International Oncology, 2015, 42(6): 455-457.

References

［1］ Kanner AA, Bokstein F, Blumenthal DT, et al. Surgical therapies in brain metas tasis［J］. Semin Oncol, 2007, 34(3): 197-205. ［2］ Ammircati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidecebasedclinical practice guideline［J］. J Neurooncol, 2010, 96(1): 85-96. ［3］ Mahmood U, Kwok Y, Regine WF, et al. Wholebrain irradiation for patients with brain metastases still the standard of car［J］. Lancet Oncol, 2010, 11(3): 221-222. ［4］ Minniti G, Salvati M, Muni R, et al. Stereotacti radiosurgery plus wholebrain radiotherapy for treatment of multiople metastases from nonsmall cell lung cancer ［J］. Anticancer Res, 2010, 30(7): 3055-3061. ［5］ Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brainradiotherapy for brain metastases［J］. J Neurooncol, 2013, 113(3): 459-465. ［6］陈秀军, 肖建平, 李祥攀, 等. 立体定向放疗与全脑放疗在多发脑转移瘤治疗中的作用分析［J］. 中华放射肿瘤学杂志, 2012, 21(1): 1-5. ［7］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinom［J］. Neuro Oncol, 2012, 14(4): 491-495. ［8］ Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metastases from nonsmall cell lung cancer［J］. Lung Cancer, 2010, 68(2): 264-268. ［9］ Ortuzar W, Hanna N, Pennella E, et al. Brain metastases as the primary site of relapse in two randomized phase pemetrexed trials in advanced nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(1): 24-30. ［10］ Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as firstline chemotherapy for advanced nonsmallcell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase Ⅱ trial (GFPC07-01)［J］. Ann Oncol, 2011, 22(11): 2466-2470. ［11］ Dinglin XX, Huang Y, Liu H, et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patientswith brain metastases of lung adenocarcinoma: a singlearmphase Ⅱ clinical trial［J］. J Neurooncol, 2013, 112(3): 461-466. ［12］ Chargari C, Pacaut C, Le Moulec S, et al. First assessment of wholebrain radiation therapy combined with pemetrexedbased chemotherapy in non-smallcell lung carcinoma: data on safety and efficacy［J］. Anticancer Drugs, 2013, 24(7): 736-742. ［13］ Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma［J］. Neuro Oncol, 2012, 14(4): 491-495. ［14］ Cortot AB, Geriniere L, Robinet G, et al. Phase Ⅱ trial of temozolomideand cisplatin followed by whole brain radiotherapy in non small cell lung cancer patients with brain metastases: a GlotGFPC study［J］. Ann Oncol, 2006, 17 (9): 1412-1417. ［15］ Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced nonsmall cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib［J］. Clin Cancer Res, 2010, 16(23): 5873-5882. ［16］ Wu YL, Zhou C, Cheng Y, et al. Aphase Ⅱ study (CTONG0803) of erlotinib as secondline treatment in advanced nonsmall cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after firstline chemotherapy (CT)［J］. J Clin Oncol, 2011, 29(1): 7605. ［17］ Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation［J］. Lung Cancer, 2012, 77(3): 556-560. ［18］ Welsh JW, Komaki R, Amini A, et al. Phase Ⅱ study of erlotinib with concurrent wholebrain radiation therapy for patients with brain metastases from nonsmall cell lung cancer［J］. J Clin Oncol, 2013, 31(7): 895-902. ［19］ Ettinger DS, Akerley W, Borghaei H, et al. Nonsmall cell lung cancer, version 2.2013［J］. J Natl Compr Canc Netw, 2013, 11(6): 645-653. ［20］ Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial［J］. Lancet, 2004, 363(4): 1665-1672.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.